GelteqGELS +2.16%10 Days Payable is 0.00 as of Jun. 2025. GuruFocus rates GELS with a GF Score™ of 10/100. The stock has 3 warning signs investors should review. Among 920 Drug Manufacturers companies, Gelteq ranks worse than 108695.54% on this metric.
The historical rank and industry rank for Gelteq's Days Payable or its related term are showing as below:
During the past 6 years, Gelteq's highest Days Payable was 1919.02. The lowest was 591.08. And the median was 1255.05.
GELS's Days Payable is not ranked *
in the Drug Manufacturers industry.
Industry Median: 90.835 * Ranked among companies with meaningful Days Payable only.
Gelteq's Days Payable
stayed the same
from Jun. 2024 (0.00) to Jun. 2025 (0.00).
Gelteq Days Payable Related Terms
Gelteq Days Payable Historical Data
* Premium members only.
The historical data trend for Gelteq's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Gelteq's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gelteq Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gelteq's Days Payable distribution charts can be found below:
* The bar in red indicates where Gelteq's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Gelteq's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gelteq (GELS) has a Days Payable of 0.00 as of Jun. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Gelteq and its competitors. Over the past decade, Gelteq's Days Payable has ranged from 591.08 to 1,919.02. According to the industry distribution chart, Gelteq ranks #999999 out of 920 companies in the Drug Manufacturers industry.
Is Gelteq's Days Payable too high?
Gelteq's current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 591.08 to a high of 1,919.02. Based on the distribution chart, Gelteq ranks #999999 out of 920 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Gelteq has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Gelteq's Days Payable compare to INM and LVRLF?
According to the Drug Manufacturers industry distribution chart, Gelteq ranks #999999 out of 920 companies for Days Payable. This places Gelteq in the lower half of its industry. The industry median Days Payable is 90.84. Historically, Gelteq's own Days Payable has ranged from 591.08 to 1,919.02 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Gelteq and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gelteq's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gelteq stock overvalued right now?
Gelteq (GELS) has a current Days Payable of 0.00. The current Days Payable is 0.00. Gelteq's overall GF Score™ is 10/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Gelteq (GELS), the current Days Payable is 0.00 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Gelteq Ltd is a clinical and science-based company focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products, preserving the simplicity, accessibility, and efficacy of oral delivery. Its principal products are edible gels and their application in gel-based dosage forms across pets, sports, pharmaceutical, over-the-counter, and nutraceutical categories, leveraging its patent pending multiple ingredient dosage forms. The company develops and tests gel-based delivery systems for humans and pets and focuses on out-licensing its technology to companies to create products that can be manufactured and sold, while continuing to manufacture existing products under license on a white label basis.
10GF Score
Get the complete analysis for GELS
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GELS has been successfully added to your 